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A 
recent article published by Britschgi 
 et al. in Cancer Cell, “JAK2/STAT5 
Inhibition Circumvents Resistance to 
PI3K/mTOR Blockade: A Rationale 
for Cotargeting These Pathways in 
Metastatic Breast Cancer,” describes a 
positive feedback loop of JAK2/STAT5 
activation that drives resistance to PI3K/
mTOR inhibition in breast cancer. The 
authors found that genetic or pharmaco-
logical inhibition of JAK2 circumvents 
resistance to PI3K/mTOR inhibition 
and go on to show the efficacy of com-
bined PI3K/mTOR and JAK2 inhibi-
tion on reducing cancer cell number, 
tumor growth, and metastasis as well as 
increasing in vivo survival. These results 
provide strong support for combination 
therapy with JAK2/STAT5 and PI3K/
mTOR inhibitors in breast cancer. Here 
we discuss how the article by Britschgi 
et al. proposes a novel mechanism to 
explain how breast cancer cells overcome 
inhibition of a key signaling pathway 
driving cell proliferation. We also discuss 
the interplay between activation of the 
transcription factors STAT5 and STAT3 
in breast cancer.
The authors’ findings pertain to triple-
negative breast cancer (TNBC), a clini-
cally aggressive subtype of breast cancer 
defined by lack of expression of estro-
gen receptor, progesterone receptor, and 
human epidermal growth factor-related 
2 (HER2) amplification. Accounting for 
about 15% of all invasive breast cancers, 
TNBCs do not respond to hormonal 
therapy or targeted antibodies to HER2. 
Some TNBCs respond to conventional 
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chemotherapy, and others harboring 
mutations in the breast cancer suscep-
tibility gene 1 (BRCA1) have deficient 
homologous recombination repair, sen-
sitizing them to poly ADP-ribose poly-
merase (PARP) inhibitors.1 Still, TNBCs 
have limited treatment options and are 
characterized by high rates of metastases 
and poor prognosis.
One therapeutic strategy for TNBC is 
targeting the signaling pathways that regu-
late critical mediators of tumor formation 
and metastatic progression. Activation of 
mTOR signaling is commonly observed 
in TNBCs.2 In addition, PI3K pathway 
aberrations have been reported to occur in 
approximately one third of breast cancers, 
pointing to a critical role for this signaling 
pathway in breast tumorigenesis.3 While 
inhibiting mTOR alone has limited thera-
peutic efficacy due to activation of PI3K 
signaling that upregulates pro-survival 
genes,4 dual PI3K/mTOR inhibitors rep-
resent an effective alternative for TNBC 
therapy. In animal models, the combina-
tion of the mTOR inhibitor rapamycin 
with the cytotoxic drug cyclophosphamide 
decreases the incidence of lung metastases 
compared with treatment with rapamy-
cin alone.5,6 It has been shown that PI3K 
pathway aberrations are more common 
in hormone receptor-positive tumors and 
less common in basal-like cancers like 
TNBC,3 suggesting that PI3K muta-
tions play different roles in the pathogen-
esis of different subtypes of breast cancer. 
Although Britschgi et al. describe a mech-
anism involving JAK2/STAT5 to circum-
vent PI3K/mTOR inhibition in TNBC, 
hormone receptor-positive tumors, which e24635-2  JAK-STAT  Volume 2 Issue 4
aggressive features (low histologic grade, 
lymph node negative status, sensitiv-
ity to chemotherapy) than tumors with 
activated STAT3 alone, suggesting that 
the tumor-suppressive effect of STAT5 
activation may be dominant over the 
tumor-promoting effect of STAT3 acti-
vation. Interestingly, STAT5-mediated 
gene repression is dominant over STAT3-
mediated gene induction for shared target 
genes.9 Breast tumors with co-activation of 
STAT5 and STAT3 are also more likely to 
be estrogen- or progesterone-receptor pos-
itive, making them sensitive to hormonal 
therapy, and less likely to be triple-nega-
tive and thus more clinically aggressive. 
In a panel of primary breast tumors, 29% 
display dual activation of STAT3 and 
STAT5, 40% display STAT3 activation 
alone, and only 7% display activation of 
STAT5 alone.9 The relatively small num-
ber of breast cancers with STAT5 activa-
tion alone suggests that STAT5 activation 
may limit the aggressiveness of tumor 
cells, most likely via its physiologic func-
tion of promoting breast epithelial cell 
differentiation.8 In light of evidence that 
STAT5 activation is associated with dif-
ferentiated breast tumors with more favor-
able prognoses while STAT3 is associated 
with more aggressive cancers, it is some-
what surprising that Britschgi et al. dis-
cover an apparently contradictory role for 
STAT5 activation in driving resistance to 
PI3K/mTOR inhibition. Given the dual 
functions of STAT5 in promoting pro-
liferation as well as differentiation, the 
net effect of STAT5 activation on breast 
cancer pathogenesis may depend on other 
molecular events in the cell. The authors 
also report that TNBC lines have a higher 
baseline of phosphorylated STAT5 than 
luminal breast cancer cell lines. However, 
others have consistently observed con-
stitutive activation of STAT3 instead of 
STAT5 in TNBC cell lines.9,17
In summary, Britschgi et al. show that 
activation of JAK2/STAT5 signaling 
in response to PI3K/mTOR inhibition 
enhances the invasiveness and metastatic 
behavior of TNBC cells. The authors 
demonstrate that JAK2/STAT5 hyperac-
tivation drives resistance to PI3K/mTOR 
inhibitors by first restoring activation of 
AKT downstream of PI3K inhibition 
and then upregulating IL-8 secretion, a 
in suppressing the invasive capacity of 
breast cancer cells.12,13 Restoring PRL 
receptor expression in TNBC cell lines 
decreases their invasive capacity while 
blocking JAK2/STAT5 in luminal breast 
cancer cell lines increases their invasive-
ness, suggesting that PRL activation of 
STAT5 restricts the metastatic potential 
of breast tumors. Conversely, accumulat-
ing epidemiologic data strongly suggest 
that circulating PRL levels are associated 
with increased risk of developing estrogen 
receptor (ER) positive, but not ER nega-
tive tumors like TNBCs.14,15 These diver-
gent effects of PRL in breast cancer may 
reflect the hormone’s dual physiological 
effects on promoting proliferation as well 
as differentiation in preparation for lacta-
tion. Taken together, these data implicate 
STAT5 as playing both a tumor-suppres-
sive and neoplastic role in breast tumors.
In contrast to STAT5 activation, 
STAT3 activation has been associated 
with a worse prognosis in breast cancer 
patients in part due to its effect on evasion 
of apoptosis. This may contribute both to 
resistance to therapy and to subsequent 
recurrence. Whether a cell undergoes 
apoptosis is largely based on competition 
between pro- and anti-apoptotic proteins 
in the mitochondria. Anti-apoptotic pro-
teins like Bcl-2 normally sequester pro-
apoptotic proteins from binding to and 
activating Bak/Bax, which form pores 
in the mitochondrial outer membrane to 
trigger cell death.16 STAT3 is known to 
upregulate the Bcl-2 family of anti-apop-
totic proteins, and Bcl-2 and Bcl-xl expres-
sion levels decline with JAK2 inhibition. 
The PI3K/AKT pathway also controls 
expression of mitochondrial apoptotic 
regulatory proteins, and inhibiting PI3K/
mTOR leads to decreased levels of the 
inactive form of the pro-apoptotic protein 
Bad. Since STAT3 and PI3K signaling 
both modulate mitochondrial apoptosis, 
inhibiting both pathways may further 
tip the balance of pro- and anti-apoptotic 
proteins in favor of cell death. Indeed, 
Britschgi et al. found that combined inhi-
bition of PI3K/mTOR and JAK2/STAT5 
leads to activation of the pro-apoptotic 
protein Bim and degradation of the anti-
apoptotic protein Mcl-1.
Breast tumors with co-activation of 
STAT5 and STAT3 generally have less 
more commonly harbor PI3K pathway 
aberrations, may rely on other mecha-
nisms to circumvent PI3K/mTOR inhibi-
tion. More studies are needed to elucidate 
the mechanisms by which modulation of 
signaling pathways drives tumor resis-
tance to anti-cancer therapies.
Since the neoplastic phenotype of a 
cell is largely driven by its pattern of gene 
expression, another treatment strategy for 
TNBC focuses on targeting the transcrip-
tion factors that are inappropriately acti-
vated in these tumors. STAT5 and STAT3 
are two closely related members of the 
STAT family of transcription factors that 
regulate the expression of genes involved 
in cell growth, survival, and angiogen-
esis.7 In normal cells, STAT signaling is 
tightly regulated by inhibitory molecules 
including suppressor of cytokine signal-
ing (SOCS) proteins, protein inhibitor 
of activated STAT (PIAS) proteins, and 
protein tyrosine phosphatases. Cancer 
cells frequently have persistent STAT acti-
vation, from hyperactivation of upstream 
tyrosine kinases or loss of function of 
negative regulators, which can then con-
tribute to malignant transformation.8 In 
cancer cells with inappropriate constitu-
tive STAT3 activation, inhibition of this 
protein leads to a reversion of the malig-
nant phenotype and cell death whereas 
normal cells lacking STAT3 activation are 
unharmed. Although STAT5 and STAT3 
are structurally similar and recognize sim-
ilar DNA response elements, these factors 
play contrasting roles in normal mam-
mary function. STAT5 promotes termi-
nal differentiation of mammary epithelial 
cells necessary for lactation while STAT3 
promotes involution of the mammary 
gland following weaning. In addition, 
STAT5 and STAT3 have been shown to 
exert opposing effects on the expression of 
select target genes such as Bcl-6 in breast 
cancer cells.9
Thus far STAT5 activation has been 
associated with a more favorable progno-
sis in breast cancer patients. Studies per-
formed in five different cohorts of breast 
cancer patients showed decreasing STAT5 
activation with disease progression.10 
STAT5 mediates the effects of prolactin 
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To our knowledge, this publica-
tion is the first description of a JAK2/
STAT5 hyperactivation mechanism by 
which tumors escape from PI3K/mTOR 
inhibition. The clinical benefit from the 
combined treatment regimen proposed 
by Britschgi et al. is potentially of great 
importance for TNBCs, which are clini-
cally aggressive and highly metastatic 
tumors. Therefore, this research high-
lights the importance of understanding 
the interactions among signaling path-
ways in cancer cells in order to improve 
the efficacy of cancer therapies.
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